Recurrent Breast Cancer Completed Phase 1 / 2 Trials for Sorafenib (DB00398)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00217399Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerTreatment